Nadolol eye drops in glaucoma and ocular hypertension: a controlled clinical study of dose response and duration of action.
The betablocker nadolol was investigated with respect to dose-response relationship and duration of action on the basis of single-drop application in four groups of ten volunteers each. A significant dose-dependent IOP reduction could be verified between 0.3% and 2% drug concentration with increasing duration of action. The maximum IOP effect for the above concentrations was between 8 and 11.6 mmHg 3 h after drug application. The duration of action was more than 6 h for 0.3% and more than 9 h for 15 and 2% nadolol. Nadolol eye drops produced no effects on blood pressure or heart rate with either concentration and no ocular irritation.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D009248:Nadolol; D011412:Propanolamines / Q000494:pharmacology / Q000627:therapeutic use*; D011897:Random Allocation; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D009248:Nadolol